BBA
TNGX icon

Baker Bros. Advisors’s Tango Therapeutics TNGX Stock Holding History

Baker Bros. Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-750,000
Closed -$5.78M – 102
2024
Q3 		$5.78M Hold
750,000
– – 0.06% 63
2024
Q2 		$6.43M Hold
750,000
– – 0.08% 57
2024
Q1 		$5.96M Hold
750,000
– – 0.07% 60
2023
Q4 		$7.42M Hold
750,000
– – 0.08% 57
2023
Q3 		$8.45M Hold
750,000
– – 0.05% 49
2023
Q2 		$2.49M Hold
750,000
– – 0.01% 89
2023
Q1 		$2.96M Hold
750,000
– – 0.02% 82
2022
Q4 		$5.44M Hold
750,000
– – 0.03% 77
2022
Q3 		$2.71M Hold
750,000
– – 0.02% 95
2022
Q2 		$3.4M Hold
750,000
– – 0.02% 87
2022
Q1 		$5.68M Hold
750,000
– – 0.03% 82
2021
Q4 		$8.21M Hold
750,000
– – 0.04% 81
2021
Q3 		$9.7M Buy
+750,000
New +$8.99M 0.04% 78

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baker Bros. Advisors's TNGX Position: Q4 2024 in Review

Baker Bros. Advisors sold out of Tango Therapeutics (TNGX) in Q4 2024, closing a stake of 750,000 shares — an estimated $5.78M sold.

Baker Bros. Advisors first reported a position in TNGX in Q3 2021 and held it in 13 quarters. The position peaked at $9.7M in Q3 2021. 137 funds tracked by Wall St. Rank hold TNGX as of Q4 2024.

  • Baker Bros. Advisors reported no remaining Tango Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Baker Bros. Advisors sold 750,000 Tango Therapeutics shares in Q4 2024, an estimated $5.78M.
  • Baker Bros. Advisors first reported a position in Tango Therapeutics in Q3 2021 and held it in 13 quarters.
  • Baker Bros. Advisors's Tango Therapeutics position peaked at $9.7M in Q3 2021.
  • 137 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2024.

Based on Baker Bros. Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.